Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03867383 · ClinicalTrials.gov registry record · Phase 1
Calcium Chloride for Prevention of Uterine Atony During Cesarean
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03867383: Completed Phase 1 study, sponsored by Stanford University.
NCT03867383 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03867383, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
In this pilot study, investigators will administer calcium chloride or placebo to pregnant women undergoing Cesarean delivery who have been identified as high risk for hemorrhage due to poor uterine muscle contraction, or atony. They will assess whether a single dose of calcium given immediately after the delivery of the fetus decreases the incidence of uterine atony and bleeding for the mother. The pharmacokinetics of calcium chloride in pregnant women will also be established. Data from this pilot study of 40 patients will be used to determine sample size and appropriateness of a larger randomized clinical trial.
Interventions
- DRUG Placebo
- DRUG Calcium Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2021-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03867383
The ClinicalTrials.gov registry entry for NCT03867383 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03867383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03867383 about?
NCT03867383 is a clinical study titled "Calcium Chloride for Prevention of Uterine Atony During Cesarean". In this pilot study, investigators will administer calcium chloride or placebo to pregnant women undergoing Cesarean delivery who have been identified as high risk for hemorrhage due to poor uterine muscle contraction, or atony. They will assess whether a single dose of calcium given immediately aft...
What is the current status of trial NCT03867383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-03-15. Estimated completion is 2021-08-15.
What interventions are being tested in trial NCT03867383?
The interventions under investigation include: Placebo (DRUG), Calcium Chloride (DRUG).
Who is sponsoring clinical trial NCT03867383?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.